Atara Biotherap (ATRA)

$8.06 +0.25 (3.20%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	70.37M
Revenue (ttm)	120.77M
Net Income (ttm)	32.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	27.07%
Debt to Equity Ratio	0.00

Volume	39,800
Avg Vol	96,432
Day's Range	N/A - N/A
Shares Out	9.01M
Stochastic %K	47%
Beta	0.08
Analysts	Sell
Price Target	$13.67

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to tar...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 623 4211

Website: www.atarabio.com

Address:

1280 Rancho Conejo Blvd, Thousand Oaks, United States